AlphAIAlphAI — Financial news for AI agents
financial-news.co.ukOCT 62 min read$OPCH

CD&R, McKesson agree $5.8bn buyout of Option Care Health

CD&R and McKesson (MCK) agreed to acquire Option Care Health (OPCH) for $32.05 per share, valuing it at $5.8bn. Option Care shares rose 9.19% on the news, trading at a premium of 37-43% over recent lows. CD&R will hold majority ownership, while McKesson takes a minority stake, taking Option Care private.

Original reporting
financial-news.co.uk
Published Oct 6, 2026, 1:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 3:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CD&R, McKesson agree $5.8bn buyout of Option Care Health — source image
Source · financial-news.co.uk
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The deal provides a clear premium to Option Care shareholders, creating short‑term arbitrage opportunities, while McKesson gains a strategic foothold in infusion services.

02

Market read

First‑report M&A of mid‑cap size, immediate price reaction, and sector consolidation implications.

03

What to watch

Potential regulatory clearance delays and the impact of elevated borrowing costs on CD&R's leverage.

Relevance 9/10Novelty 9/10Timing: today

Background

The article reports the first public disclosure of a $5.8 bn take‑private transaction for Option Care Health, involving private equity firm CD&R and distributor McKesson.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health announced a definitive agreement to be taken private at $32.05 per share, valuing the company at about $5.8 bn, causing the stock to jump 9.2% on the day.

Expected impact

likely upward pressure as the premium is locked in, but upside limited after the announcement

Evidence & confidence

The deal price is a clear premium to recent trading ranges; arbitrage opportunities narrow quickly.

$MCKNeutralMedium confidence
Context

McKesson Corp. disclosed a minority stake purchase in the Option Care buyout, joining CD&R as a co‑buyer.

Expected impact

slight positive bias as investors view the strategic expansion, but no immediate price move expected

Evidence & confidence

McKesson's share price typically reacts modestly to acquisition stakes; the transaction size is small relative to its market cap.

Market effects

Sector

Healthcare services consolidation may lift peers in infusion therapy and specialty care.

Regional

U.S. healthcare sector sees modest bullish pressure from the deal.

Global

Limited; primarily a U.S. domestic M&A event.

Counterpoint

What could challenge this read

If the premium is already reflected, the buyout could face financing strain in a high‑rate environment, pressuring the stock.

Key entities

  • Company
    Option Care Health

    Home and alternate‑site infusion therapy provider being taken private.

  • Company
    McKesson Corp.

    Healthcare distributor acquiring a minority stake in the buyout.

  • Private Equity
    CD&R

    Lead private‑equity sponsor acquiring majority control.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 7
$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

wfmz.com2 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min
OCT 7
$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

finchannel.com2 min